Exploring treatment options in renal transplantation: The problems of chronic allograft dysfunction and drug-related nephrotoxicity

Transplantation

Volumn 71, Issue 11 SUPPL., 2001, Pages

  Campistol, J M ^a   Grinyo J M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG MECHANISM; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL;

CALCINEURIN; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 0035876629     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (126)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Survival trends in long-term first cadaver-donor kidney transplants
3. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia
4. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs
5. Histopathology of calcineurin inhibitor-induced nephrotoxicity
6. Management of cardiovascular risk posttransplantation
7. Impact and management of hyperlipidemia post-transplantation
8. Mechanisms of nephrotoxicity
9. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: Implications for human renal disease progression
10. Cyclosporin-induced endothelial cell injury
11. Tubular toxicity of cyclosporine A and the influence of endothelin-1 in renal cell culture models (LLC-PK1 and MDCK)
12. An in vitro model of cyclosporine-induced nephrotoxicity
13. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis
14. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis
15. Immunosuppressive agents in organ transplantation: Past, present, and future
16. Pre-transplant hypertension: A major risk factor for chronic progressive renal allograft dysfunction?
17. Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American pediatric renal transplant cooperative study
18. Risk factors for chronic rejection in renal allograft recipients
19. Early versus late acute renal allograft rejection: Impact on chronic rejection
20. Chronic rejection: An update on the mechanism
21. Chronic rejection and its risk factors
22. Chronic rejection
23. Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study
24. Chronic rejection and hypertension: A chicken-and-egg problem
25. Post-transplant hypertension and chronic renal allograft failure
26. Role of hypertension in chronic renal allograft dysfunction
27. Angiotensin II blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy
28. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy
29. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group
30. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
31. Acute cyclosporine A-induced nephrotoxicity: A rabbit model
32. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function
33. Cyclosporine A directly constricts intrarenal arterioles
34. Cyclosporin in therapeutic doses increases renal allograft vascular resistance
35. Endothelins in the normal and diseased kidney
36. Endothelin in organ transplantation
37. Cyclosporin A induces prepro endothelin-1 gene transcription in human endothelial cells
38. Endothelin release by rabbit proximal tubule cells: Modulatory effects of cyclosporine A, tacrolimus, HGF and EGF
39. Effects of cylosporin A on the synthesis, excretion, and metabolism of endothelin in the rat
40. Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine
41. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506
42. FK506-induced endothelin release by cultured rat mesangial cells
43. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines
44. Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats
45. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670
46. Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction
47. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1
48. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles
49. Endothelin, angiotensin II and adenosine in acute cyclosporine A nephrotoxicity
50. Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporine A nephrotoxicity in rats
51. An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs
52. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells
53. Acute cyclosporine A nephrotoxicity in rats: Which role for renin-angiotensin system and glomerular prostaglandins?
54. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet
55. Fibrogenic effects of cyclosporin A on the tubulointerstifium: Role of cytokines and growth factors
56. Drug interactions and consequences of sodium restriction
57. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet
58. Altered vascular responses in cyclosporine-treated rats
59. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat
60. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats
61. Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats
62. Effect of cyclosporine administration on renal hemodynamics in conscious rats
63. Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation
64. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity
65. Reduction of chronic cyclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046
66. The reversal of experimental cyclosporine A nephrotoxicity by thromboxane synthetase inhibition
67. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats
68. Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis
69. Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival survival in rats with renal isograft
70. Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats
71. Effects of L-arginine on cyclosporin-induced alterations of vascular NO/cGMP generation
72. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms
73. Cyclosporin A increases nitric oxide activity in vivo
74. Transcriptional induction of endothelial nitric oxide gene by cyclosporine A. A role for activator protein-1
75. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells
76. Cyclosporine A-induced arteriolopathy
77. Chronic injury of human renal microvessels with low-dose cyclosporine therapy
78. The long-term course of cyclosporine-associated chronic nephropathy
79. Apoptosis and necrosis: Mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line
80. Cyclosporin A nephrotoxicity: Site selective toxicity using LLC-PK1 and MDCK cells
81. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells
82. P-glycoprotein and drug therapy in organ transplantation
83. Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits
84. Actions of endothelin-1 on cultured rat renomedullary interstitial cells are modulated by nitric oxide
85. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide inhibition in rats
86. In vivo hyperexpression of transforming growth factor-beta 1 in mice: Stimulation by cyclosporine
87. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function
88. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity
89. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin
90. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity
91. 1 and matrix proteins in chronic cyclosporine nephrtoxicity
92. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts
93. Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function
94. 1 in transplant patients with chronic allograft nephropathy
95. Hypertension following kidney transplantation
96. Management of hypertension after transplantation
97. Effects of transplantation on the renin angiotensin system (RAS)
98. Cardiovascular morbidity and risk factors in renal transplant patients
99. Calcineurin inhibitors cause renal afferent activation in rats: A novel mechanism of cyclosporine-induced hypertension
100. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
101. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
102. Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat
103. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
104. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection
105. Synergistic effects of rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse
106. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
107. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival
108. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
109. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
110. Management strategies for nephrotoxicity
111. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy
112. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation
113. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: Beneficial effect of low doses in early post-transplantation period
114. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-β expression with preserved renal blood flow
115. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year
116. Morphological and functional renal effects of long-term low-dose cyclosporine A treatment in patients with rheumatoid arthritis
117. Sirolimus (rapamycin)-based' therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
118. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
119. Is nonnephrotoxic immunosuppression a possibility?
120. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo
121. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury
122. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels
123. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
124. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
125. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model